SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (19432)3/23/2006 1:54:47 PM
From: Ian@SI  Respond to of 52153
 
P.,

Many thanks. All info provided is new to me. I've concluded that this is closer to a proven technology than just another scheme which may or may not have any therapeutic value.

Ian



To: dr.praveen who wrote (19432)3/23/2006 3:43:45 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Thanks praveen and Ian.

The Noxxon approach seems a very clever twist on aptamers that they claim solves a number of issues like immunogenicity and stability. Sort of stock I'd like to own if they were public.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News